Can a targeted drug combo outperform standard chemo for tough lung cancer?
NCT ID NCT07739758
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is testing whether a new experimental drug called YL201, when combined with the immunotherapy serplulimab, can help people with extensive-stage small cell lung cancer live longer compared to the current standard treatment (carboplatin and etoposide plus serplulimab). The study enrolls adults who have not received prior systemic treatment for this advanced cancer. Participants are randomly assigned to one of the two treatment groups, and the main goals are to measure overall survival and progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YL201 (an experimental antibody-drug conjugate) combined with serplulimab (an immunotherapy)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for extensive-stage small cell lung cancer, potentially improving survival compared to current standard care.
- What could go wrong
- This is a phase III trial, but results are not yet known. The experimental drug may not prove more effective or could cause unexpected side effects. Success in earlier phases does not guarantee final approval.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110042, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
- New combo therapy targets tough lung cancer in early trial
- New PET scan probe could sharpen lung cancer detection